Skip to main content

Abbvie Value Stock - Dividend - Research Selection


ISIN: US00287Y1091, WKN: A1J84E

Market price date: 27.01.2022
Market price: 135,97 USD

Abbvie Fundamental data and company key figures of the share

Annual reports in USD
Key figures 21-02-2021
Cash flow
Net operating cash flow 17.588.000.000
Capital Expenditures -798.000.000
Free cash flow 16.789.999.616
Balance sheet
Total Equity
Liabilities & Shareholders equity 150.565.000.000
Income statement
Net income 4.616.000.000
Eps (diluted) 2,720
Diluted shares outstanding 1.673.000.000
Net sales/revenue 45.804.000.000

Fundamental ratios calculated on: 27-01-2022

Key figures 27-01-2022
Cash flow
P/C 12,77
P/FC 13,55
Balance sheet
Income statement
Div. Yield3,61%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization224.566.788.096,00 USD
CountryUnited States
IndicesRussell 3000,S&P 500,MSCI World Index
Raw Data SourceUS GAAP in Millionen USD
Stock Split

Description of the company

AbbVie Inc. (AbbVie) is a research-based pharmaceuticals company. The Company discovers, develops, and commercializes advanced therapies. AbbVie's portfolio of products include a line of adult and pediatric pharmaceuticals, which includes HUMIRA, metabolics/hormones products, virology products, endocrinology products, dyslipidemia products and other products. AbbVie products are used to treat rheumatoid arthritis, psoriasis, Crohn's disease, human immunodeficiency virus (HIV), cystic fibrosis complications, low testosterone, thyroid disease, Parkinson's disease and complications associated with chronic kidney disease, among other indications. In October 2012, AbbVie initiated a comprehensive Phase III program for hepatitis C virus (HCV) genotype one.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


2 Dirt-Cheap Dividend Stocks to Buy and Hold Forever

Dividend stocks are worth serious consideration, especially given the current state of the economy. With inflation near 40-year highs in the U.S., dividends can be a source of supplemental income for those who need it. And since the rise in prices can eat into investors' returns,

The Retiree's Dividend Portfolio - Jane's December Update: Celebrating 15% Year-Over-Year Dividend Growth

Jane's retirement accounts generated $2,580.62 of dividend income for December 2021 vs. $1,946.03 for December 2020. Read more about how the stocks performed.

Top Analyst Reports for AbbVie, Edwards Lifesciences & Johnson Controls

Wednesday, January 26, 2022The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including AbbVie Inc. ABBV, Edwards Lifesciences Corp. EW, and Johnson Controls Internationa

AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth

The market expects AbbVie (ABBV) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2021. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful f

2 Reasons to Buy AbbVie Stock, and 1 Reason to Sell

With 2021 net revenue estimated at $56.2 billion, AbbVie (NYSE: ABBV) is one of the world's most successful pharmaceutical companies. And given its massive pipeline of late-stage, drug-development programs in immunology, oncology, and aesthetics, the company likely has the opport

Karyopharm's (KPTI) Eltanexor Gets Orphan Drug Tag for MDS

Karyopharm Therapeutics Inc. KPTI announced that the FDA has granted Orphan Drug designation to its novel oral, selective inhibitor of nuclear export compound, eltanexor, for the treatment of myelodysplastic syndromes (“MDS”).

2 Stocks to Buy No Matter What Happens in 2022

The U.S. equity market has been quite volatile in January 2022. Rising omicron cases, sticky inflation, which is expected to result in rate hikes, and now weaker-than-anticipated earnings results for tech stocks have negatively affected investor sentiment. Against this backdrop,

Noteworthy Tuesday Option Activity: ABBV, AMED, REKR

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 32,524 contracts have traded so far, representing approximately 3.3 million underlying shares. That amounts to about 44.1% o

AbbVie: Skyrizi And Rinvoq Latest FDA Approvals Bode Well For Humira Patent Loss

Total projected sales by AbbVie for each Skyrizi and Rinvoq will be $7.5 billion by 2025. I believe that ABBV stock remains a great long-term buy.

Vertex Investors Look Out...AbbVie Data In Cystic Fibrosis Coming Soon

AbbVie will be releasing Phase 2 data for its Cystic Fibrosis drugs that could potentially compete with Vertex’s drugs. Read what this means for VRTX investors.